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SUMMARY 
Hedgehog (Hh) proteins are 
morphogens that mediate many 
developmental processes. Hh signaling is 
significant for many aspects of embryonic 
development, whereas dysregulation of this 
pathway is associated with several types of 
cancer. Hh proteins require heparan sulfate 
proteoglycans (HSPGs) for their normal 
distribution and signaling activity. Here we 
have used molecular modelling to examine 
the heparin-binding domain of Shh. In 
biochemical and cell biological assays the 
importance of specific residues of the 
putative heparin-binding domain for 
signaling were assessed. It was determined 
that key residues in hShh involved in 
heparin and HSPG syndecan-4 binding and 
biological activity included the well known 
cationic Cardin-Weintraub motif (lysine 
32-lysine38), but also a previously 
unidentified major role for lysine 178. The 
activity of Shh mutated in these residues 
was tested by quantitation of alkaline 
phosphatase activity in C3H10T1/2 cells 
differentiating into osteoblasts and 
hShh-inducible gene expression in PANC1 
human pancreatic ductal adenocarcinoma 
(PDAC) cells. Mutated hShhs such as 
K37/38S, K178S and particularly 
K37/38/178S that could not interact with 
heparin efficiently had reduced signaling 
activity compared to wild type hShh or a 
control mutation (K74S). In addition, the 
mutant hShh proteins supported reduced 
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proliferation and invasion of PANC1 cells 
compared with control hShh proteins, 
following endogenous hShh depletion by 
RNAi knockdown. The data correlated with 
reduced Shh multimerization where the 
K37/38 and/or K178 mutations were 
examined. These studies provide a new 
insight into the functional roles of hShh 
interactions with HSPGs, which may allow 
targeting this aspect of hShh biology in, for 
example, PDAC. 
 
INTRODUCTION 
Hedgehog proteins (Hhs) are morphogens 
that spread from producing cells to specify a 
diverse range of cell fates in a wide variety of 
tissues, in a concentration-dependent manner 
[1]. In mammals, all three members of the Hh 
family, Sonic (Shh), Indian (Ihh) and Desert 
(Dhh) Hedgehog, display a variety of roles in 
embryonic development, adult homeostasis, 
and cancer [2]. Perturbations to the Hh 
signaling pathway manifest themselves in 
disease; for instance, over-activity of the 
pathway can lead to oncogenesis while 
decreased activity can result in developmental 
malformations. It has been estimated that 25% 
of all human tumors require Hh signaling to 
maintain tumor cell viability [3]. Therefore, to 
establish potent Hh inhibitors and biomarkers 
are significant goals for diagnosis and 
treatment of diverse human tumors. 
 In vertebrates, Shh signaling regulates the 
development of many diverse, tissue types that 
includes examples of ectodermal, mesodermal 
and endodermal lineage [4,5]. Recent findings 
on Gli-stimulated transcription of cyclin B1 and 
cyclin D1 suggest that, through regulation of 
cyclin-dependent cell proliferation, the pathway 
is able to guide tissue specification as well as 
tissue maintenance [6]. Mutations in Hh 
pathway genes or dysregulation of the pathway 
are associated with certain cancers. 
Inappropriate Shh signaling is frequently 
related to tumor initiation and maintenance, e.g. 
basal cell carcinomas (BCCs) and 
medulloblastomas are often characterised by 
inactivation of the Shh receptor Ptc1 or 
constitutive activation of the signal transducer 
Smo [7,8], manifested as increased 
transcription of target genes of the Shh pathway 
[9]. That Shh acts as a dominant oncogene was 
shown in studies from mice and humans, in 
which ectopic expression of Shh results in BCC 
[10,11]. In addition, ectopic expression of Gli1 
or Gli2 in mice results in tumor formation, 
indicating that activating downstream 
components of the pathway is sufficient to 
initiate tumor growth [12]. Shh signaling also 
plays a role in the pathogenesis of chronic 
myelogenous leukemia, gliomas and multiple 
myeloma [13-15]. 
 Shh signaling is active during pancreatic 
organogenesis and low-level expression of 
Hip1, Ptch1, Smo, Ihh and Dhh has been 
detected within mature islets and cultured cell 
lines [16,17]. In pancreatic ductal 
adenocarcinoma (PDAC), the Shh signaling 
pathway is frequently upregulated [18]. In in 
vitro co-culture assays, the PDAC cell lines 
PANC-1 and ASPC-1 (which overexpress Shh) 
were able to activate Gli transcription in 
co-cultured C3H10T1/2 cells [19]. Moreover, 
implanting the human PDAC cell line HPAF-II 
into Ptc1-LacZ mice, revealed upregulated Ptc1 
in the stromal cells surrounding the implant, but 
not in the tumor tissue. These data suggest that 
upregulation of Shh in PDAC cells can 
influence tumor growth via paracrine 
interactions with adjacent normal stroma. 
Additionally, gene expression studies in PDAC 
precursor lesions have demonstrated high 
expression levels of Shh target genes, including 
Gli1 and Ptc1, and cyclin D1. 
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 Heparan sulfate proteoglycans (HSPGs) 
have crucial roles in many developmental 
signaling systems involved in cell fate 
determination and differentiation, interacting 
with members of the Wnt, Hh, transforming 
growth factor-β (TGF-β) and fibroblast growth 
factor (FGF) pathways [20]. HSPGs are 
extracellular matrix (ECM) and cell surface 
macromolecules that consist of a core protein 
with one or more covalently attached heparan 
sulfate (HS) chains. Syndecans and glypicans 
are two major cell surface HSPGs. Both are 
integral membrane proteins: syndecans are 
transmembrane proteins whereas glypicans are 
linked to the plasma membrane by a 
glycosylphosphatidylinositol (GPI) linkage. 
Perlecans are secreted HSPGs that are mainly 
distributed in the ECM [21]. The HS chains are 
the major site of interaction between 
proteoglycans and morphogens such as Hh, 
growth factors, cytokines and ECM molecules. 
HSPGs mediate Hh function in invertebrate and 
vertebrate embryos through regulation of 
morphogen stabilisation, release and signaling 
activity [20]. They are also believed to facilitate 
the presentation of Hh ligand to 
signal-receiving cells and participate in 
promoting cell surface microdomains/lipid rafts 
in which the crucial molecules are assembled 
into functional complexes [20]. 
 Although dual lipidation of Hh is essential 
for membrane association, HSPGs also 
contribute to cell surface association. HSPGs 
may be required for multimer formation [22] 
and might be linked to Hh by Shifted, a secreted 
Wnt Inhibitory Factor homologue. The 
N-terminal region of Shh contains a basic motif 
that is conserved across vertebrates. It conforms 
to the Cardin-Weintraub motif (XBBBXXBX, 
where B is a basic residue and X is any residue) 
that was shown to be canonical for the 
interaction of some heparin-binding growth 
factors to heparin. In the case of human Shh, 
this region, consisting of residues 32-38 (with 
the sequence KRRHPKK) plays a role in the 
binding of Shh to HS. Experiments have shown 
that mutations in this domain are linked to a 
decrease in the proliferative activity induced by 
ShhN on cerebellar granule cell precursors, for 
example [23]. 
 Here we have investigated the interaction 
between human (h) Shh and HSPGs through 
expression of mutant Shh proteins that are 
compromised in heparin-binding. A series of in 
vitro and cell-based assays reveal an important 
role for lysine 178 of Shh, as predicted from our 
molecular modelling of Shh-heparin 
interactions. This is in addition to an essential 
role of the cationic region between residues 32 
and 38. The biological functions of purified 
wild-type and mutated hShhs that have reduced 
or negligible interaction with heparin have been 
tested by paracrine alkaline phosphatase 
induction in C3H10T1/2 cells as well as 
induction of Ptc and Gli1 mRNA and protein in 
PANC1 PDAC cells. In addition, RNAi 
knockdown of endogenous hShh using 
synthetic oligonucleotides in PANC1 cells was 
followed by treatment with these mutated 
hShhs in proliferation and invasion assays. In 
all cases, biological activity of Shh was 
markedly reduced in parallel with reduced 
heparin affinity. A potentially key underlying 
property of the mutated hShhs was shown to be 
markedly reduced multimerization compared to 
the wild type protein. 
 
EXPERIMENTAL PROCEDURES 
Modelling of Heparin/Hh and Heparin/Shh 
interactions - Docking calculations were 
performed using the program Autodock as 
described previously [24]. This protocol allows 
a simple and computationally inexpensive 
search of the whole protein surface for the 
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optimum heparin binding site, but does not 
predict the ‘pose’ of the ligand within the 
binding site, and does not allow for any 
flexibility in the protein. Two pentasaccharide 
structures based on the solution structure of 
heparin (1HPN.pdb) were used as ligands [25]; 
both had the sequence 
D-GlcNSO3
-
6SO3
--(1→4)-L-IdoA2SO3
--(1
→4)-D-GlcNSO3
-
6SO3
--(1→4)-L-IdoA2SO3
-
-(1→4)-D-GlcNSO3
-
6SO3
-
 (abbreviated to 
GlcNS6S-IdoA2S-GlcNS6S-IdoA2S-GlcNS6S
). The IdoA residues were set to the 
1
C4 
conformation in one of the pentasaccharides 
and the 
2
S0 conformation in the other, to reflect 
the conformational mobility of this saccharide 
residue. Both of these ligands were allowed 
rotations around exocyclic bonds except for the 
glycosidic linkage bonds. A further 
undecasaccharide model with the sequence 
(GlcNS6S-IdoA2S)5-GlcNS6S was also used 
as a ligand; in this model no bonds were 
allowed to rotate, the structure remaining rigid. 
The coordinates for mouse Shh were taken 
from 1VHH.pdb [26], and for human Shh from 
chain A of the 1.85Å crystal structure 
3M1N.pdb [27]. 
Cell culture and Syndecan-4 purification 
-  C3H10T1/2 fibroblasts generously provided 
by Dr. Kay Grobe were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 8% fetal bovine serum. 
PANC1 cells purchased from ATCC 
(CRL-1469) were maintained in DMEM 
supplemented with 8% fetal bovine serum 
(FBS). Full length rat syndecan-4 cDNA in 
pCAGIP (28) was transfected into Cos-7 cells 
and stable transfectants selected over 7 days 
from 48h after transfection by 0.5 µg/ml 
puromycin. Cos-7 cells constitutively shed 
syndecan-4 from the cell surface, enabling 
purification from conditioned media. Cultures 
were transferred over 5-7 days into a 
serum-free medium (Panserin 604; PAN 
Biotech, Aidenbach, Germany) and medium 
was harvested every 3-4 days. Syndecan-4 
ectodomain was purified by conventional 
anion exchange chromatography as described 
(29) and verified by western blotting. All cell 
cultures were routinely tested for mycoplasma 
contamination. 
Cloning and Expression/Purification of 
Recombinant Shh - The human Shh cDNA 
clone was purchased from the I.M.A.G.E. 
Consortium (Accession No: BC111925, Clone 
ID: 40080739). To express and purify active 
Shh from Escherichia coli, 
pET41a(+)-ShhNC24II was constructed. 
Site-directed mutagenesis using the 
QuickChange Kit (Stratagene) was used to 
replace Cys24 with Ile-Ile and to add a stop 
codon after Gly197.   In these bacterially 
expressed Shh proteins, the Ile-Ile replacing 
Cys24 is to mimic the hydrophobic nature of the 
N-terminal palmitoylated Cys24 of natural 
mammalian expressed Shh, following 
enterokinase-catalysed cleavage of the GST; 
the stop codon is to terminate the protein at the 
site at which it would be autocleaved 
mammalian cells. When expressed naturally in 
mammalian cells a palmitate would be added to 
the N-terminus and a cholesterol would be 
added to the C-terminus after internal 
autocleavage at Gly197; neither of these lipid 
additions takes place in bacterial cells so the 
bacterially expressed proteins are modified to 
increase the potency of the recombinant Shh 
proteins.  This is similar to the approach taken 
for production of commercially available rShh 
(R&D Systems, Recombinant Human Sonic 
Hedgehog (C24II), NTerminus, Catalog 
Number 1845SH). Then, ShhNC24II cDNA 
was cloned into the pET-41a(+) expression 
vector at the PshAI and SacI sites to form 
pET41a(+)-ShhNC24II. We next generated 
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pET41a(+)-ShhNC24II/K37.38S, 
pET41a(+)-ShhNC24II/K178S, 
pET41a(+)-ShhNC24II/K37.38.178S and 
pET41a(+)-ShhNC24II/K74S by site-directed 
mutagenesis. E. coli DH5α and XL1 blue were 
used as competent cells for general cloning.  
All restriction enzymes were purchased from 
NEB and all PCR products were 
sequence-verified. Bacterial cultures of 
GST-ShhNC24II clones were grown overnight 
and induced with a final concentration of 0.1 
mM isopropyl-β-D-thiogalactopyranoside 
(IPTG) overnight at 20 °C. Cells were 
harvested (4,000 × g, 30 min) then suspended 
in ice-cold PBS (150 mM NaCl, 2.7 mM KCl, 
10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4) 
and lysed in the presence of 0.2% lysozyme 
and 1% Triton X-100 for 30 min on ice with 
sonication. The extracts were centrifuged to 
remove the cellular debris and GST-ShhC24II 
fusion proteins were captured on columns of 
Glutathione-Sepharose 4B (GE Healthcare). 
Recombinant enterokinase (rEK) (S•Tag™ 
rEK Purification Kit, Novagen) was applied 
directly to the beads to release ShhNC24II 
proteins. Residual rEK was removed using 
Ekapture Agarose beads, leaving the purified 
19kDa soluble ShhNC24II proteins. 
 To establish a mammalian overexpression 
system of fully-lipidated hShh, a 
pcDNA-DEST40-hShh expression vector was 
constructed using the Gateway cloning system 
(Invitrogen) based on recombination between 
an entry vector and a destination vector. 
pENTR223.1-hShh (DNAFORM) was 
propagated in E. coli using spectinomycin (100 
μg/mL) for selection while pcDNA-DEST40 
(Invitrogen) was selected by chloramphenicol 
(30 μg/mL) and the pcDNA-DEST40-hShh 
construct by ampicillin (100 μg/mL). Then, 
pcDNA-DEST40-hShhK37.38S, 
pcDNA-DEST40-hShhK178S, 
pcDNA-DEST40-hShh K37.38.178S and 
pcDNA-DEST40-hShhK74S were obtained by 
site-directed mutagenesis.  The constructs 
were verified by sequencing and Western 
blotting of expressed Shh following 
transfection into PANC1 cells with 
Lipofectamine 2000 (Invitrogen). 
 Characterisation of purified human 
ShhNC24II protein -. Western blotting and dot 
blotting were carried out using both rabbit 
polyclonal anti-Shh (H-160; Santa Cruz 
Biotechnology, sc-9024) and function-blocking 
mouse monoclonal anti-Shh 5E1 
(Developmental Studies Hybridoma bank, 
USA) on 50 ng of each purified protein. 
Secondary antibodies were horseradish 
peroxidase (HRP)-conjugated goat anti-mouse 
IgG or HRP-conjugated goat anti-rabbit IgG 
(Southern Biotech). Bound immunocomplexes 
were detected using enhanced 
chemiluminescence detection reagents (Pierce) 
and were visualised by exposing the membrane 
to x-ray film (Fuji medical x-ray film, Super 
RX, 11860). Protein concentrations were 
measured using Bio-Rad Protein Assay 
Reagent (Bio-Rad, Richmond, CA, USA) 
following the manufacturer’s protocol. 
Interactions of human Shh proteins with 
syndecan-4 proteoglycan were assessed by dot 
blotting. Syndecan-4 (0-10 μg) was absorbed 
to the nitrocellulose membrane followed by 
blocking with 5% skim milk. 1 μg/μl Shh 
proteins (ShhNC24II, ShhNC24II/K37.38S, 
ShhNC24II/K178S, ShhN C24II/K37.38.178S 
or ShhNC24II/K74S in PBS were applied to 
the membrane at 37 °C for 1 h; the bound Shhs 
were detected with H160 antibody. In control 
experiments, 1 μg/μl hShh proteins were mixed 
with heparin (sodium salt, Sigma, 1 µg/µl) at 
room temperature for 15 min. The 
pre-incubated mixture was applied to the 
membrane following the procedures described 
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above. 
 Heparin binding assay - Purified wild 
type and mutant hShhNC24II proteins 
(ShhNC24II/K37.38S, ShhNC24II/K178S, 
ShhNC24II /K37.38.178S and 
ShhNC24II/K74S; 100 µg in 100 µL 
phosphate buffer: 2.7 mM KCl, 10 mM 
Na2HPO4 and 1.8 mM KH2PO4, pH 7.4) were 
applied to a heparin affinity column (HiTrap 
Heparin HP, 0.7 x 2.5 cm; GE Healthcare) 
using an ÄKTA system (Pharmacia LKB). 
Elution was with a linear gradient of 0-0.7 M 
NaCl that was confirmed by continuous 
conductivity measurement. A positive control 
for the chromatography, the HepII domain of 
fibronectin, was kindly provided by Dr. Atsuko 
Yoneda (University of Copenhagen). The 
eluates were examined by Shh dot blotting 
with 5E1 anti-Shh antibody. In control 
experiments, 10 μg ShhNC24II were applied to 
heparin-agarose columns with or without 
preincubation with 1 mg/ml heparin (sodium 
salt, Sigma). Binding and elution were 
monitored by dot blotting with 5E1 antibody. 
 Differentiation of C3H10T1/2 osteoblast 
precursor cells - alkaline phosphatase (AP) 
assay - Cells were plated at 1 X 10
5
 per well in 
6-well plates. Purified hShhNC24II proteins 
were added to the culture medium the day after 
plating at a concentration of 300, 500, 1000 or 
2000 ng/ml. Monoclonal antibody 5E1 is a 
specific inhibitor of the Shh pathway by 
binding to Shh and neutralising its activity [30]. 
To some samples, 5E1 (10 μg/ml) was added 
together with hShh proteins. Five days after 
treatment, C3H10T1/2 cells were lysed (in 150 
μl 1% Triton X-100 in PBS, pH 7.4 with 
complete protease inhibitor cocktail (Roche) 
and Shh activity was tested by measuring 
alkaline phosphatase induction in the cells at 
405 nm using a microplate reader (Bio-Rad 
Lumimark), accomplished by incubation with 
150 μl 120 mM p-nitrophenol phosphate 
(Sigma), 50 mM MgCl2 and 1 M 
diethanolamine (Sigma) at room temperature 
for 30 min. Assays were performed in 
triplicate. 
 Semi-quantitative Reverse 
Transcription-PCR - After treatment with 
1μg/ml purified proteins (ShhNC24II, 
ShhNC24II/K37.38S, ShhNC24II/K178S, 
ShhNC24II/K37.38.178S or ShhNC24II/K74S) 
for 24 h, PANC1 cells were analyzed by 
Reverse Transcription-PCR (RT-PCR). Total 
RNA extraction with Trizol (Invitrogen) was 
followed by cDNA synthesis by random 
priming of 1μg of total RNA with SuperScript 
II Reverse Transcriptase kit (Invitrogen), 
according to the manufacturer’s instructions. 
The following primers were used for the 
subsequent PCR: human GAPDH (sense, 
5’-TTCATTGACCTCAACTACAT-3’; 
antisense, 
5’-GTGGCAGTGATGGCATGGAC-3’); 
human β-actin (sense, 
5’-ATGGATGAGGATATCGCTGCG-3’; 
antisense, 
5’-CTAGAAGCATTTGCGGTGCAC-3’); 
human Shh (sense, 
5’-CGCACGGGGACAGCTCGGAAGT-3’; 
antisense, 
5’-CTGCGCGGCCCTCGTAGTGC-3’) [31]; 
human Ptc (sense, 
5’-GGTGGCACAGTCAAGAACA-3’; 
antisense, 
5’-ACCAAGAGCGAGAAATGG-3’) [31]; 
human Smo 
(sense,5’-TTACCTTCAGCTGCCACTTCTA
CG-3’; antisense, 
5’-GCCTTGGCAATCATCTTGCTCTTC-3’) 
[32]; human Gli1 (sense, 
5’-TTCCTACCAGAGTCCCAAGT-3’; 
antisense, 
5’-CCCTATGTGAAGCCCTATTT-3’) 32]. 
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PCR with Taq DNA Polymerase (Invitrogen) 
used the following conditions: 30 cycles of 30 
s at 95° C, 30s at 60° C, and 2min/kb at 72° C.  
PCR products were resolved by electrophoresis 
on 1.7% agarose gels and visualised by 
ethidium bromide staining. 
 Functional assay of hShh proteins in 
PANC1 cells: Western blotting. Four h after 
plating PANC1 cells (3 X 10
5
 cells per well in 
a 6-well plate), 1μg/ml purified hShh proteins 
(ShhNC24II, ShhNC24II/K37.38S, 
ShhNC24II/K178S, ShhNC24II/K37.38.178S 
and ShhNC24II/K74S) with or without 5E1 
antibody (10 μg/ml) were added to the culture 
medium. Cells were harvested 48 h later and 
analyzed by Western blotting. Goat polyclonal 
anti-patched (Ptc; ab51983) and mouse 
monoclonal α-tubulin (DM1A, ab49928) were 
from Abcam, while rabbit polyclonal 
anti-Gli-1 (H-300, sc-20687) was purchased 
from Santa Cruz Biotechnology. Secondary 
antibodies were HRP-conjugated goat 
anti-mouse IgG, HRP-conjugated goat 
anti-rabbit IgG or HRP-conjugated donkey 
anti-goat IgG (Southern Biotech). Bound 
immunocomplexes were detected using 
enhanced chemiluminescence detection. 
 Human (h)Shh RNAi knockdown -. 
Human Shh siRNA pooled oligomers 
(sc-29477) were from Santa Cruz 
Biotechnology, Inc.  The negative control was 
SilencerR FAMTM-Labelled Negative Control 
#1 siRNA (Ambion).  siRNA transfections 
were carried out with FuGENE 6 Transfection 
Reagent (Roche) by plating 0.3 million cells 
per well in a 6-well plate and 6 h later treating 
with 10 pmol siRNA oligomers and 3 μl 
FuGENE 6 Transfection Reagent. Western 
blots and dot blots of conditioned media were 
analyzed and quantitated by densitometry to 
assess the extent of Shh reduction. 
Immunoblotting was carried out using rabbit 
polyclonal anti-Shh H-160 on cultures 
harvested 24 h, 48 h and 72 h after siRNA 
transfection. 
Shh oligomerisation assay - In these assays, 
siRNA treatment to knock down endogenous 
Shh and plasmid transfection for wild type or 
mutant Shh protein expression were carried out 
sequentially in PANC1 cells. PANC1 at 1 x 
10
5
 cells/well in a 6-well format (2 ml medium, 
no antibiotics) were treated with 10 pmol of 
Shh siRNA with FuGENE 6 transfection agent 
(as above) to knock down endogenous wild 
type Shh. After 16 h, pcDNA-DEST40-hShh 
expression vectors were transfected into the 
cell and 72 h after siRNA transfection, culture 
medium was changed to serum-free medium 
for 24 h. Conditioned media were collected, 
clarified by and centrifugation and analyzed by 
gel filtration chromatography (ÄKTA Protein 
Purifier, Amersham Biosciences) on a 
Superdex 200 10/300 GL column (Amersham 
Biosciences) equilibrated with phosphate 
buffer, detailed above, at 4° C. The molecular 
mass standards Blue dextran, 2000kDa; 
Apoferritin, 480 kDa; Alcohol dehydrogenase, 
150 kDa; Albumin, 67 kDa and recombinant 
Human ShhN (C24II) (R&D Systems, Inc.), 19 
kDa were used to calibrate the column. Eluted 
fractions (1 ml) were collected, trichloroacetic 
acid (TCA)-precipitated, then assayed by dot 
blotting with H-160 Shh antibody. 
 PANC1 invasion assay - Biocoat Matrigel 
invasion chambers with 8 μm pores in 6-well 
plates (BD Biosciences) were used in invasion 
assays. To determine the effect of mutated Shh 
proteins on PANC1 invasion ability, 72 h 
before PANC1 cells were plated to the 
chambers the cells were pretreated with hShh 
siRNA reagent together with exogenous 
recombinant Shh proteins (1 μg/ml). Shh 
proteins-containing media were changed every 
48 h. PANC1 cells were detached with 5mM 
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EDTA in PBS. Detached cells were 
resuspended in serum-free DMEM and added 
to the upper compartment of the chambers (1 X 
10
5
 cells/well). Conditioned medium (8% FBS) 
was placed in the lower chambers. After 24h of 
incubation at 37° C, the cells on the upper 
surface were completely removed by wiping 
with a cotton swab, and then the filter was 
fixed with 100% methanol and stained with 
crystal violet solution (0.5% (w/v) crystal 
violet in 25% (v/v) methanol). Cells that had 
migrated from the upper to the lower side of 
the filter were photographed and counted with 
a light microscope (10 fields/filter). 
 PANC1 proliferation and flow cytometry - 
Proliferation was measured with the vital dye 
carboxyfluorescein diacetate, succinimidyl 
ester (CFSE ; Sigma). The essence of this 
assay is that cells are loaded with dye that 
becomes successively diluted by division into 
daughter cells at each mitosis. Briefly, after 24 
h of synchronization in serum-free medium, 
cells were treated with hShh siRNA together 
with purified hShh proteins (1 μg/ml each 
hShhNC24II, hShhNC24II/K37.38S, 
hShhNC24II/K178S, 
hShhNC24II/K37.38.178S or 
hShhNC24II/K74S), or 5E1 blocking antibody 
(10 µg/ml) separately, and cells were labelled 
with 2.5μM CFSE at 37° C for 15 min.  Shh 
proteins-containing media were replenished 
every 48 h. In some cases, 5E1 antibody 
treatment was carried out 72 h after 
synchronization, to mimic siRNA KD kinetics. 
After 8 days stimulation, cell division was 
indicated by decreased CF fluorescence 
intensity per cell, as analyzed by flow 
cytometry. For flow cytometer assessment, 
PANC1 cells were removed from plates with 
ice-cold FACS buffer (1% FBS and 2 mM 
EDTA in PBS) and resuspended in the same 
buffer. Cells were analyzed with a 
FACScalibur flow cytometer.  
 Statistical analysis -. All experiments 
were replicated at least three times, and 
statistical significance was measured by 
using the two-tailed t test. A p value <0.05 
was taken to indicate statistical 
significance.  All target signals from 
Western blots and dot blots were 
quantified by Scion Image software. 
 
RESULTS 
 
Molecular Modelling of Shh–heparin 
interactions. The crystal structure of mouse Shh 
(1VHH.pdb) is truncated at the N-terminus, 
starting at K39 (the equivalent of K38 in the 
human sequence). Docking calculations for 
both pentasaccharides and undecasaccharides 
indicated that the optimum heparin-binding site 
involves this N-terminal residue (Fig. 1A), and 
in addition, residue K179 distant in the 
sequence (K178 in the human sequence). A 
structure of human Shh (1M1N.pdb) has also 
been determined, that retains more of the 
N-terminal sequence which does not form part 
of the globular structure but adopts an extended 
structure stabilized by crystal contacts. This 
N-terminal sequence contains several basic 
residues, and docking to this structure indicates 
that residues R28, K32 and K34 can form a 
heparin-binding site independently of the 
globular, structured protein (Fig. 1B). This was 
the case not only for the relatively short, partly 
flexible pentasaccharide ligands, but also for 
the extended and rigid undecasaccharide 
structure. As the protein structure is rigid in the 
docking protocol used [24], the extended 
conformations of the N-terminal sequences in 
1VHH.pdb and 1MIN.pdb are retained in the 
final models of the docked complexes, which 
may well not be an accurate reflection of their 
behaviour in solution. 
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This raised the question of whether the 
distant K179 identified in the truncated murine 
Shh structure is a genuine part of the 
heparin-binding site of Shh, or is an artefact of 
the docking calculation. To address this, 
specific mutations in human Shh, including 
that of K178 were carried out for a series of 
biological assays. 
 Characterisation of purified human Sonic 
Hedgehog (hShh) proteins. To examine the 
folding of mutated hShh proteins purified from 
E. coli, two different hShh antibodies, 5E1 (a 
Shh neutralizing antibody recognizing the 
active site) and H-160, were used in Western 
blotting (Fig. 2A) and dot blotting (Fig. 2B). 
The 5E1 antibody was used to define the 
degree of native folding of purified hShh 
proteins [33]. Similar reactivity of wild type 
and mutant forms of the Shh proteins to 5E1 in 
dot blots suggests that they are all correctly 
folded to a similar degree. The H-160 antibody 
was used as a loading control. 
 Lysine 37/38 and lysine 178 of hShh play 
crucial roles in interactions with heparin and 
HSPG. Previous studies in Drosophila [34] and 
vertebrate systems [35] suggested that by 
forming a multimeric complex with specific 
HSPGs - perlecan and glypican – the efficiency 
of Shh signaling could be facilitated. To 
confirm that hShhNC24II could interact with 
heparin, we initially used a small scale heparin 
affinity assay and verified the specificity in the 
presence of competing free heparin (data not 
shown). Next, to determine the key residues on 
hShh involved in heparin binding, affinity 
chromatography on a heparin-agarose column 
with gradient salt elution was employed. In this 
assay, wild type (ShhNC24II) and mutated 
recombinant hShh proteins 
ShhNC24II/K37.38S, ShhNC24II/K178S, 
ShhNC24II/K37.38.178S and 
ShhNC24II/K74S) were analyzed with elution 
by a 0 to 0.7 M NaCl gradient (Fig. 2C). The 
results showed that ShhNC24II had a peak 
elution at 0.54 M NaCl which was similar to 
ShhNC24II/K74S (0.53 M NaCl), whereas 
ShhNC24II/K37.38S and ShhNC24II/K178S 
exhibited reduced heparin affinity, being eluted 
at 0.4 M NaCl and 0.3M NaCl, respectively). 
The triple mutant, ShhNC24II/K37.38.178S 
was essentially lacking in heparin binding 
(n=5), suggesting that not only lysine residues 
37 and 38 (of the previously identified 
Cardin-Weintraub motif) but also lysine178 of 
hShh play critical roles in heparin, and 
presumably HSPG, binding. Moreover, lysine 
74 plays no part in binding to heparin, 
verifying that this mutation serves as a 
negative control. 
 In further dot blotting experiments with 
syndecan-4 ectodomain, which is substituted 
with HS chains, similar data were obtained as 
seen with heparin interactions. Wild type 
ShhNC24II and ShhNC24II/K74S bound to the 
proteoglycan, in a manner sensitive to heparin 
competition (Supplementary Fig. 1). The triple 
mutant ShhNC24II/K37.38.178S bound poorly, 
while the ShhNC24II/K37.38S and 
ShhNC24II/K178S forms were intermediate 
(Supplementary Fig. 1). Therefore, it appears 
that K178 contributes substantially to 
interactions with HSPGs (at least syndecan-4) 
as well as free heparin glycosaminoglycan. 
 Bioactivity of mutated hShhs in 
C3H10T1/2 cells: heparin-binding is required 
to induce alkaline phosphatase activity. To 
examine the biological functions of the 
different hShhNC24II proteins, the 
C3H10T1/2 osteoblast precursor cell line was 
utilized, which expresses alkaline phosphatase 
(AP) when stimulated by Shh [22]. As shown 
in Fig. 3A, both ShhNC24II- and 
ShhNC24II/K74S-supplemented medium (1 
μg/ml) induced C3H10T1/2 differentiation into 
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AP-producing osteoblasts, demonstrating 
competent biological activity of these purified 
hShh proteins. Lysine 74 mutation to serine 
had no impact in this assay. In contrast, 
ShhNC24II/K37.38S and ShhNC24II/K178S 
were reduced by 50-75% in their activity in the 
assay (Fig. 3A). Of note, the single K178S 
mutant Shh protein gave a greater reduction in 
AP expression than the K37/38S mutant 
compared to the wild type protein. Moreover, 
the ShhNC24II/K37.38.178S triple mutant 
exhibited a further reduction in AP induction. 
However, when hShh proteins were increased 
to 2 μg/ml the differences in AP activity 
between them decreased, but remained 
statistically significant (Fig. 3A). To verify 
whether the induced AP activity was due 
directly to the hShh proteins, we used 
Shh-neutralising antibody 5E1 [33] as a 
specific inhibitor of Shh-induced C3H10T1/2 
differentiation (Fig. 3B). The biological 
activity of Shhs was significantly inhibited by 
5E1 co-treatment. In summary, these data 
show that ShhNC24II/K37.38S, 
ShhNC24II/K178S and particularly 
ShhNC24II /K37.38.178S mutants are greatly 
reduced in their ability to bind heparin and to 
induce osteoblast differentiation. High doses of 
recombinant Shh proteins were required in this 
assay, consistent with the lack of 
post-translational lipid modifications of the 
bacterially expressed proteins. 
ShhNC24II/K37.38.178S fails to 
stimulate signaling through the Shh pathway in 
PANC1 cells.To further study the signaling 
activity of mutated Shhs, semi-quantitative 
reverse transcription-polymerase chain 
reaction (RT-PCR) and Western blots for 
proteins that represent Shh target genes were 
performed on PANC1 cells pre-treated with 1 
μg/ml hShhs for 24 or 48 h. Therefore, the 
signaling activity obtained from both assays 
was a consequence of endogenous hShh plus 
exogenous purified Shh proteins in PANC1 
cells. Previous studies reported that Shh 
responses are mediated primarily by the 
transcription factors Gli1, Gli2, Gli3 [12] and 
the receptor Ptc. Unlike Gli2 and Gli3, which 
can function as either transcriptional activators 
or repressors, Gli1 only functions as an 
activator, and only one isoform of Gli1 has been 
identified. In RT-PCR (Fig. 4A, B), GAPDH 
and β-actin were used as controls. In 
comparison with untreated cells, 5E1 treatment 
strongly reduced both Ptc and Gli1 expression 
by 70% and 79% respectively. On the other 
hand, compared to ShhNC24II and 
ShhNC24II/K74S positive controls, 
ShhNC24II/K37.38S and ShhNC24II/K178S 
both failed to increase Ptc and Gli1 (mRNA 
levels for Ptc and Gli1 were decreased by 
>20% and >25% respectively, P<0.001), 
whereas Shh and Smoothened (Smo) mRNA 
levels were unchanged. More importantly, 
ShhNC24II/K37.38.178S addition resulted in 
further reduction in Ptc and Gli1 by >28% and 
>47% respectively compared with ShhNC24II 
treated cells (P<0.001). 
 Immunoblotting was carried out to 
confirm the RT-PCR results (Fig. 4C, D). In 
Western blots for Ptc, both ShhNC24II/K178S 
and ShhNC24II/K37.38.178S
 
addition led to 
marked reduction in protein levels by 44% and 
60% respectively (P<0.001), compared to 
ShhNC24II- and ShhNC24II/K74S-treated 
cells. In addition, less Gli1 was induced in 
response to ShhNC24II/K178S and 
ShhNC24II/K37.38.178S with 53% and 57% 
reduction respectively (P<0.005) compared to 
ShhNC24II and ShhNC24II/K74S proteins. 
Therefore, modifications of wild type Shh 
affecting potential HSPG binding sites (K37, 
38 and 178) resulted in a large reduction in the 
activity in both C3H10T1/2 and PANC1 assays 
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(Figs. 3 and 4), suggesting that HSPG 
interactions are essential for Shh signaling in 
these cell systems. Mutation of either the 
K37/38 or of K178 reduced activity 
significantly and to a comparable degree. 
However, mutation of all three lysine residues 
was required for almost complete inactivation 
of Shh biological activity, suggesting that they 
contribute additively to HS interactions. 
Mutant Shh with reduced heparin affinity
 
cannot rescue inhibition of PANC1 
proliferation caused by endogenous hShh 
depletion.A dependency of PANC1 
proliferation on Shh was demonstrated by 
treating cells with the inhibitory Shh antibody 
5E1. The data show that carboxyfluorescein 
(CF) intensity after 8 days in culture of cells 
treated with 5E1 on day 1 was ~30 times 
higher than untreated cells (Fig. 5), suggesting 
that untreated PANC1 cells replicate 4-5 times 
more than 5E1-treated cells over 8 days. 
Moreover, cells treated with 5E1 from day 4 
(used to mimic Shh siRNA kinetics) contained 
~8 times higher CF intensity compared to 
untreated cells. Both results support the 
interpretation that PANC1 proliferation is 
Shh-dependent. Knockdown (KD) of Shh by 
siRNA treatment gave similar results to the use 
of 5E1 antibody from day 4. Western blots 
confirmed >90% Shh depletion after siRNA 
(Supplementary Fig. 2). A scrambled siRNA 
used as a negative control showed similar CF 
fluorescence levels to untreated cells. 
In a background of endogenous Shh 
depletion (denoted Shh KD), PANC1 cells 
were exposed to wild type or mutant Shh 
proteins. Flow cytometry profiles of Shh KD 
cells treated with either ShhNC24II/Shh or 
ShhNC24II/K74S yielded similar results to 
untreated cells (mean fluorescence intensity; 
MFI <1000, Fig. 5), suggesting that both 
ShhNC24II and ShhNC24II/K74S proteins are 
able to rescue reduced PANC1 proliferation 
caused by Shh depletion (P<0.001). In contrast, 
purified ShhNC24II/K37.38S and 
ShhNC24II/K178S proteins added to culture 
medium showed less ability to rescue PANC1 
proliferation caused by endogenous Shh KD, 
with ~6 times increased MFI compared to 
untreated cells (P<0.001). Furthermore, 
ShhNC24II/K37.38.178S-treated Shh KD cells 
showed a similar result to Shh KD cells alone, 
with ~8 times increased MFI compared to 
untreated cells (P<0.001), indicating that 
ShhNC24II/K37.38.178S is defective in 
stimulating PANC1 proliferation in 
comparison to ShhNC24II and 
ShhNC24II/K74S. These results suggest that 
HS binding plays an important role in PANC1 
proliferation through Shh signaling since 
ShhNC24II or ShhNC24II/K74S could rescue 
inhibited PANC1 caused by hShh RNAi KD, 
but the triple lysine mutant 
ShhNC24II/K37.38.178S was unable to do so. 
Mutant Shh proteins with reduced 
heparin affinity do not promote PANC1 
invasive behavior. To investigate the 
contribution of Shh to invasive potential of 
PANC1 cells, we carried out invasion assays 
with exogenous Shhs treatment combined with 
endogenous Shh RNAi KD. To confirm that 
PANC1 invasion is dependent on Shh signaling, 
the effect of 5E1 treatment on PANC1 invasion 
was determined. The results (Fig. 6) showed a 
significant decrease in the number of invading 
cells after 5E1 treatment (33±8 cells/well) 
compared with untreated control cells (271±25 
cells/well). These data were then verified by 
Shh KD which resulted in migration of 43±11 
cells/well. These results suggested that the 
invasive ability of PANC1 cells was at least 
partly a result of autocrine Shh signaling. 
When endogenous Shh depletion and either 
ShhNC24II or ShhNC24II/K74S were 
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combined in the invasion assay, a significant 
increase in the number of invasive PANC1 
cells was observed (325±32 and 302±45 
cells/well respectively) compared to Shh KD 
alone, suggesting that ShhNC24II and 
ShhNC24II/K74S could restore inhibited 
PANC1 invasion. In contrast, 
ShhNC24II/K37.38S and ShhNC24II/K178S 
combined with Shh KD showed a significant 
decrease in the number of invasive PANC1 
cells with 192±15 and 191±18 cells/well 
respectively (Fig. 6). Furthermore, 
ShhNC24II/K37.38.178S combined with Shh 
KD reduced invasion to a level (86±17 
cells/well) similar to that observed for Shh KD 
cells, indicating that ShhNC24II/K37.38S, 
ShhNC24II/K178S and particularly 
ShhNC24II/K37.38.178S provided less 
stimulus for PANC1 invasion. It should be 
noted that invasion assays over 24 h, such as 
this, can be influenced by proliferation. 
However, we found the doubling time for 
PANC1 cells to be ~51 h (data not shown), 
which cannot explain the clear effects of Shh 
proteins on migratory behavior. Therefore, 
HSPGs appear to play a crucial role in PANC1 
invasion mediated by Shh signaling. 
ShhNC24II /K37.38.178S is defective in 
forming multimeric complexes in PANC1 cells.  
Interaction with HSPGs has been suggested to 
be essential for the formation of Shh 
multimeric complexes [34,35]. To assess 
multimer formation, PANC1 cells were 
depleted of endogenous Shh by siRNA 
treatment, followed by transfection with 
vectors encoding wild type or mutant Shh. In 
this system dual lipidation of the Shh will 
occur, which may be essential for multimer 
formation. To evaluate the ability of mutated 
hShhs to form multimeric complexes, gel 
filtration followed by Shh dot blotting of each 
fraction were carried out for PANC1 cell 
conditioned media. A 19 kDa polypeptide and 
a large pool of high molecular mass complexes 
were observed in control cell media (Fig. 7). 
Higher levels of secreted Shh were found in 
medium from both untreated cells and 
scrambled RNAi-treated cells than from Shh 
KD cells, providing evidence that Shh KD 
reduced Shh expression. The majority of 
secreted Shh in PANC1 control untreated 
culture medium forms large complexes and 
only a small portion of Shh migrates as 
monomers (2.6±1.2%), confirming the results 
of a previous study [22]. In contrast, in Shh 
RNAi-treated cultured medium the total 
amount of Shh was much reduced (>90% 
reduction compared with untreated control 
cells) and higher quantities of Shh monomers 
were detected (12.7±4.5%, P<0.001), nearly 6 
times higher than untreated control medium, 
whereas media from scrambled siRNA-treated 
cells showed a similar pattern to control media 
with 1.9±1.3% monomer. Wild type Shh or 
ShhK74S expression in PANC1 cells combined 
with Shh KD treatment, either made no 
difference in the proportion of monomeric 
versus large Shh-containing complexes, or a 
slight decrease in Shh monomerisation 
(1.2±0.9% and 1.1±0.8% respectively). 
Therefore, ectopically expressed wild type and 
K74S Shh were capable of forming complexes. 
Analysis of media from hShhK37.38S 
-expressing and hShhK178S-expressing Shh 
KD cells resulted in increased monomerisation, 
25.5±5.7% and 20.4±4.6% respectively, 
(P<0.001). Notably, a further increase in the 
proportion of monomers was detected in 
ShhNC24II/K37.38.178S-expressing Shh KD 
cells (85.5±9.7%, P<0.001). In combination, 
we conclude that wild type hShh and 
hShhK74S form large complexes when 
expressed in PANC1 cells, but 
hShhK37.38.178S does not, while the 
 13 
hShhK37.38S and hShhK178S mutants were 
intermediate. 
 
DISCUSSION 
Based on developmental and biochemical 
studies in Drosophila and vertebrate systems 
there are several proposed mechanisms for 
HSPG promotion of Hh signaling. On one hand, 
Shh and Hh are secreted from cells as both 
monomeric and multimeric forms. Soluble Hh 
multimeric complexes with HSPGs are 
potentially freely diffusible, which can 
facilitate Hh bioavailability. On the other hand, 
the interaction between HSPGs and Shh may 
influence both Shh extracellular distribution 
and ability to signal as shown by perlecan’s 
ability to function as a Shh co-receptor [34]. 
Furthermore, HSPGs potentially participate in 
promoting cell surface microdomains/lipid rafts 
where the crucial molecules are assembled into 
functional complexes [36]. In this regard, the 
GPI-anchored glypican HSPGs may be 
particularly important. Therefore, HSPGs 
appear to facilitate Shh signaling cascades at 
various levels, including secretion, retention 
and stabilisation of ligands, directed trafficking 
and targeting to ligand-receiving cells. 
 In this report, the heparin-binding 
properties of Shh were examined in detail. 
Previously a single motif, comprising a 
conserved XBBBXXBX sequence, where B is 
a basic residue, and X is any residue, was 
identified in Shh [37]. This region (K32-K38) 
precisely coincides with a consensus sequence 
for heparin binding, known as the 
Cardin-Weintraub motif [23]. Much data have 
subsequently been compiled showing that this 
is only one of a number of cationic sequences 
that can bind glycosaminoglycans [38]. The 
importance of the K32-K38 region in Shh for 
binding heparin and HS has been demonstrated 
[38]. Our molecular modelling of murine Shh, 
on the other hand, suggested that another 
lysine residue K179 on the surface of Shh 
(K178 in the human sequence) may also 
contribute to overall affinity of the morphogen 
for heparin. This model included an incomplete 
flexible N-terminal domain, while a second 
model of human Shh, with a longer N-terminal 
region, suggested that the cationic K32-K38, 
with R28, formed the dominant 
heparin-binding motif. The hypothesis that 
K178 of hShh was significant for interaction 
with heparin, and HSPGs, was tested here. Our 
data support a key role for K178 in several 
different assays of hShh function. 
 First, it is apparent that mutation of two 
of the four lysine residues to disrupt the 
Cardin-Weintraub motif (K37 and K38) does 
not ablate heparin binding, as shown by 
affinity chromatography. Only when lysine 178 
is additionally mutated, does heparin affinity 
become negligible. Very similar data were 
obtained from interactions with syndecan-4 
proteoglycan.  Entirely consistent with these 
binding data, several biological assays, 
including osteoblast differentiation, and PDAC 
cell proliferation and invasion also showed the 
same trend. Alkaline phosphatase secretion by 
C3H10T1/2 cells was reduced where K37 and 
K38 were mutated to serine residues, but was 
reduced much further by additional K178 
mutation. Moreover, mutation of K178 alone 
had considerable effect, not dissimilar to the 
K37/K38 mutation. The same principles were 
noted for PANC1 proliferation and invasion of 
matrigel. The triple mutant was reduced 
four-fold in invasion-supporting activity 
compared to the wild type morphogen. 
 Multimerization of Shh is known to be a 
key facet of its biological function, and 
interaction with heparinoids is a promoter of 
this process, as is the dual lipidation of the 
protein [20]. Shh secreted from PANC1 cells 
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transfected with cDNAs encoding the same 
range of mutations, in a background of 
endogenous Shh depletion achieved by siRNA, 
was analyzed by gel filtration. Consistent with 
the cell biological experiments, it was noted 
that increasing proportions of the Shh were 
monomeric as the affinity for heparin declined. 
The triple mutant form of Shh (K37/38/178S) 
was largely monomeric. All this suggests that 
the quaternary structure and biological 
properties of Shh depend to a significant 
degree on binding of HSPGs. Therefore, given 
that the Cardin-Weintraub motif, while 
important, does not comprise the sole 
heparin-binding sequence of Shh, previous 
data can be re-evaluated. For example, work in 
mice has shown that a R34A/K38A mutation in 
Shh reduced (but did not ablate) proteoglycan 
affinity, but did not alter Ptc affinity [38]. 
Moreover, while the mutant Shh had reduced 
ability to promote proliferation, neuronal tissue 
patterning was not affected. It would be 
interesting to determine whether additional 
mutation of K178 would affect this outcome. 
Our data are, on the other hand, consistent with 
a role for HSPGs in the potentiation of Shh 
trafficking and targeting to receiving cells. 
Previous studies using mutations in the 
glypican Dlp, mutations in the Ext gene family 
of HS polymerases and truncation of the 
Cardin-Weintraub motif have suggested that 
HSPGs are critical for appropriate localization 
of Hh proteins [39,40]. 
 The data presented here suggest that a 
previously unrecognised lysine residue, K178, 
is a key component of the heparin-binding site 
of human Shh. Moreover, this residue appears 
to be highly conserved across an array of 
vertebrates, from fish to amphibians, birds and 
mammals, including primates, as is the more 
well known K32-K38 motif. Molecular 
modelling that was used to identify K178 as a 
key residue in heparin binding also indicated 
that K74 was not, and our data substantiate this 
hypothesis. Mutation of K74 to serine was 
silent in terms of all biochemical and cell 
biological assays examined here, the protein 
being essentially indistinguishable from the 
wild type. Therefore, while the molecular 
modelling of the murine sequence correctly 
predicted a role for K179, that of the human 
Shh did not. It is probably relevant that 
predicting heparin-binding sequences of 
flexible, relatively unstructured protein regions 
from docking calculations can be challenging. 
The longer, human Shh contained more 
cationic residues than the murine protein, and 
these dominated the predicted interactions. It is 
revealing that the shorter murine Shh appears 
to have offered a physiologically relevant 
insight into hShh-HSPG interactions, borne out 
by the studies reported here. 
 A number of Shh responsive genes have 
been identified, including genes that are 
involved in proliferation and tissue patterning 
e.g. Gli2, N-myc, Gli3, Cyclin D1, Cyclin D2 
and Bmi-1. In addition, it has also been shown 
that Cyclin D1, Cyclin D2 and Bmi-1 gene 
targets that require Shh-HSPG interactions are 
significant in tumor stem cell biology [41,42]. 
Also, it is interesting to note that Shh-dependent 
cancer growth can be stimulated through 
glypican overexpression in several cases, e.g. 
prostate cancer, PDAC and rhabdomyosarcoma 
[43,44]. In this work, we asked whether 
interactions with HSPGs can modulate the 
pattern of Shh-responsive gene induction and 
the biological responses to Shh in PDAC cells. 
We employed mAb 5E1 to block the Shh 
signaling pathway in PANC1 cells, resulting in 
a significant decrease in proliferation (4-5 times 
lower over 8-days) and an eight-fold reduction 
in invasiveness, suggesting that Shh signaling 
has a critical and central role in PDAC cell 
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growth and contributes to malignant 
transformation. We directly demonstrated that 
K37.38S or K178S mutant results in reduced 
proliferation compared to wild type Shh; an 
even more marked effect was noted with the 
K37.38.178S triple mutant. We also observed a 
~40% decrease in invasive cells by K37.38S or 
K178S treatment compared to wild-type Shh 
and control K74S mutant. Not surprisingly, the 
triple mutant K37.38.178S resulted in a 
four-fold reduction in invasive cells compared 
with wild-type Shh or control K74S mutant. 
Together, these findings suggest that 
Shh-HSPGs interactions promote PANC1 cells’ 
oncogenic properties at multiple levels, 
including both proliferation and invasion, 
highlighting the widespread significance of 
proteoglycans in tumorigenesis and also 
pointing out an important mediator of the 
malignant behavior of human PDAC cells. 
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FIGURE 1. Modelling of Heparin- Sonic Hedgehog (mShh) interactions. 
The three lowest energy predictions for the the heparin-mShh interaction from docking calculations 
are shown, with the protein structure exactly overlaid. The proteins are shown as ribbon diagrams 
coded red for helix, blue for beta strand and grey for loops and sequences lacking secondary structure. 
Heparin molecules are shown in stick form, coloured by element: grey for carbon, red for oxygen, blue 
for nitrogen, yellow for sulphur and white for hydrogen. A. The predicted complex between mShh 
(1VHH.pdb) and a heparin undecasaccharide, with heparin interacting residues K39 and K179 shown 
in green stick form. B. The predicted complex between hShh (3M1N.pdb) and a heparin 
undecasaccharide, with heparin interacting residues R28, K32 and K34 shown as green sticks; K38 
and K178 are shown as orange sticks. 
 
FIGURE 2. Characterisation of purified wild type and mutant hShh proteins by heparin affinity 
chromatography. Each of the five purified Shh proteins were analyzed by Western blot (A) and dot 
blot (B) with two Shh antibodies, H160 and 5E1. The latter confirms that all mutant hShh proteins 
retain appropriate conformation. Heparin binding efficacy of all five proteins was determined by 
heparin-Sepharose chromatography (C) with a linear elution gradient of 0-0.7 M NaCl in phosphate 
buffer (2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4).  
 
FIGURE 3. Differentiation of C3H10T1/2 Osteoblast Precursor Cells requires hShh with 
heparin-binding properties. C3H10T1/2 osteoblast precursor cells were cultured in the presence of 
wild type hShh and hShh mutants at 300-2000 ng/ml for 5 days (A). The relative amount of 
Shh-induced alkaline phosphatase activity was measured as described in Materials and Methods to 
determine biological activity of the morphogen. As a control, Shh-treated cells were incubated with 
5E1 anti-Shh to demonstrate specificity of Shh-induced differentiation (B). Values are mean ± S.D., 
n=9 in each group, * p-value <0.001 compared to control group ShhNC24II, ** p-value <0.001 
compared to 5E1 treatment group, ‡ p-value <0.01 compared to 5E1 treatment group. 
 
FIGURE 4. Signaling in human PDAC cells is mediated optimally by Shh with heparin-binding 
properties. Expression of Ptc and Gli1 were examined by both RT-PCR and Western blot in PANC1 
cells after treatment of cells with recombinant wild type and mutant hShh. The PCR analysis and 
immunoblotting data are shown in A and C respectively and are quantified in B and D. Values are 
mean ± S.D., n=9 in each group in RT-PCR experiments (B), * p-value <0.0001 compared to untreated 
group. ‡ p-value <0.001 compared to ShhNC24II group. In Western blotting assay (D, n=4), * p-value 
<0.0001 compared to untreated group. ‡ p-value <0.001 compared to ShhNC24II group. 
 
FIGURE 5. Mutant hShh proteins that lack heparin affinity promote lower levels of PANC1 cell 
proliferation. Both 5E1 blocking antibody treatment on Day 1 (5E1 D1) and siRNA depletion of 
endogenous Shh (Shh KD) confirmed that PANC1 proliferation is Shh responsive. 5E1 treatment on 
Day 4 (5E1 D4) was used to mimic in vivo RNAi KD kinetics. The maximum labeling was determined 
by treating cells with CFSE just before flow cytometer assessment. To study the effect of the wild type 
and mutant Shh proteins in PANC1 proliferation, 8 days after Shh siRNA transfection /hShh treatment, 
the cells were analyzed by flow cytometry. The Y-axis shows the level of CF intensity observed from 
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30,000 cells. The experiments were repeated three times in triplicate, and statistical significance was 
assessed with the two-tailed t test (**, P< 0.0001 compared to untreated group; ‡, P< 0.0001 compared 
to Shh KD group). 
 
FIGURE 6. PANC1 cell invasion in response to hShh requires the morphogen to possess 
heparin-binding properties. To study the effect of wild type and mutant Shh proteins on PANC1 
invasion, 72 h after Shhs treatment/RNAi transfection the cells were plated onto Matrigel invasion 
chambers for 24 h. Cells that migrated from the upper to the lower side of the filter were photographed 
(A) and counted with a light microscope (10 fields/filter, B). The experiments were repeated four 
times, and statistical significance was calculated with the two-tailed t test (*, P< 0.001 compared to 
untreated samples; ‡, P< 0.0001 compared to ShhNC24II/Shh KD samples). 
 
FIGURE 7. Multimerization of hShh proteins is reduced in parallel with decreased heparin 
affinity. 72 h after RNAi transfection, PANC1 conditioned media were TCA precipitated and 
examined by Western blot for Shh (A). To examine the ability of mutated hShh proteins to form 
multimers, endogenous Shh was depleted by 16 hr siRNA treatment. Ectopically expressed wild type 
or mutant hShh was achieved by cDNA transfection. After 48 h incubation, conditioned media were 
analyzed by gel filtration chromatography (Superdex 200 10/300 GL column). After TCA precipitation, 
each fraction was probed by Shh dot blot (B) The elution of molecular mass standards are shown 
across the top of the dotblot, in kD. Monomerization factor (%) = (Monomer / Monomer + Multimer) 
X 100%. 
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